Max Gelman - Endpoints News

about the author Max Gelman writes about the big-picture ideas and trends that drive the biopharma world, with particular interests in immunology, oncology and neuroscience. A graduate of Northwestern University, Max joined Endpoints in July 2020 after a few stints covering Major League Baseball and college sports. He currently lives in New York City with his fiancé and rescue dog, Rose.

author articles Updated: Roivant reports Phase 2b lupus failure for an FcRn drug Another Novartis failure; Novo drops the ‘Nordisk’; and more FDA approves Lilly's oral SERD combo for second-line breast cancer therapy Updated: Ultragenyx’s new gene therapy will cost $3.95M Axoltis says its Phase 2 study for an experimental ALS drug failed Setbacks for Novartis; Anthropic looks for a dealmaker; and more FDA places partial hold on Biohaven's ion channel drug Tyra finds ray of sunshine in otherwise cloudy Phase 2 bladder cancer data Bristol Myers claims Phase 2 success for GPRC5D-directed CAR-T FDA approves Takeda, Protagonist drug as first treatment for rare blood disorder Third death in China’s expedited trials; Merck and Moderna’s cancer vaccine win; and more Merck, Moderna declare Phase 3 success for personalized mRNA cancer vaccine Amylyx declares late-stage win with a GLP-1 antagonist in its post-ALS reset Summit and Akeso's PD-1xVEGF bispecific got a new approval in China. It came with an unwelcome surprise Trump’s MMR order; LSD drug clears Phase 3 test; and more Bicara shakes up leadership ahead of CEO departure; J&J's John Reed joins Madrigal's board Is China’s work ethic a ‘wake-up call’?; The megamerger that wasn’t; and more Merger talks between AstraZeneca, Bristol Myers are off — report Merck plans a sac-TMT combo trial with Keytruda as patent cliff looms AstraZeneca-Bristol Myers megamerger talk leaves Wall Street wanting more answers Alnylam's slump deepens; Q2 earnings roundup; and more Alnylam